What to expect from your first injection through year one—based on clinical trial data and real-world physician experience with thousands of patients.
By Dr. Teja V. Surapaneni, MD, MS • Board-Certified Internal Medicine • Updated April 2026
One of the most common questions I hear from patients starting semaglutide is: “How soon will I see results?” The answer depends on how you define “results.” Appetite changes begin within days. Meaningful weight loss takes weeks. The kind of transformation that makes your friends ask what you’re doing differently usually takes months.
Here is what the clinical data shows and what I observe in my practice, broken down month by month.
Semaglutide is a GLP-1 receptor agonist that works primarily by activating receptors in the brain that regulate appetite and satiety. These neural effects begin almost immediately after your first injection.
During the first two weeks, most patients report:
You start at the lowest dose (0.25 mg weekly) during these first weeks. This is a titration dose—it is not the therapeutic target. Its purpose is to let your GI system acclimate to the medication and minimize nausea.
By the end of the first month, most patients have lost 3–5 pounds. Some patients lose more, particularly those with higher starting BMIs. You are still on a sub-therapeutic dose (0.25–0.5 mg), so this is just the beginning.
Nausea is most common during this period, affecting roughly 40–44% of patients in the STEP 1 clinical trial. For most people it is mild and manageable. I cover strategies for dealing with it in my article on managing semaglutide nausea.
Other common early side effects include constipation, diarrhea, and mild abdominal discomfort. These typically improve as your body adjusts.
During months two and three, your physician increases your dose according to a standard titration schedule: 0.5 mg at week 5, then 1.0 mg at week 9. Each increase brings stronger appetite suppression and faster weight loss.
By the end of month 3, most patients have lost 5–8% of their starting body weight. For a 220-pound patient, that is roughly 11–18 pounds.
This is the period where the medication begins to feel truly effective. Patients report that their relationship with food is fundamentally different: they eat because they are hungry, not because food is available. Portion sizes decrease naturally. Snacking often stops entirely.
Side effects from earlier dose levels have usually resolved by now, though nausea may briefly return with each dose increase before subsiding again within a few days.
This is the period where results become visible to others. By month 6, patients in the STEP 1 trial had lost an average of approximately 10–12% of their body weight.
Your dose continues to increase during this period (1.7 mg, then the maintenance dose of 2.4 mg). At the full therapeutic dose, semaglutide is working at maximum capacity to:
Patients in this phase often report that clothing fits differently, energy levels improve, blood pressure begins to normalize, and metabolic markers (fasting glucose, HbA1c, lipid panels) start showing improvement.
This is also when diet quality becomes increasingly important. As you lose weight rapidly, preserving lean muscle mass requires adequate protein intake—I recommend 1.0–1.2 grams per kilogram of goal body weight daily. Read more in my GLP-1 diet guide.
The STEP 1 trial reported average weight loss of 14.9% of body weight at 68 weeks (approximately 16 months). Most of that loss occurs in the first 12 months, with the rate gradually slowing as you approach your new weight set point.
By months 9–12, many patients have achieved:
The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in patients on semaglutide, confirming that the benefits extend far beyond the scale.
Weight loss typically plateaus between months 12 and 18. This is not the medication failing—it is your body reaching a new equilibrium. Your physician will work with you on a long-term plan that may include:
An important note: the STEP 1 extension data showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year. This is consistent with obesity being a chronic condition that requires ongoing treatment, similar to hypertension or diabetes. Discuss long-term treatment duration with your physician.
Individual results vary significantly. Factors that influence your timeline include:
The SURMOUNT-5 head-to-head trial showed that tirzepatide produced greater average weight loss than semaglutide (20.2% vs 13.7% at 72 weeks). Tirzepatide activates both GIP and GLP-1 receptors, which may explain its enhanced efficacy. For patients seeking maximum weight loss or those who plateau on semaglutide, switching to tirzepatide is a conversation worth having with your physician. I cover this in detail in our semaglutide vs tirzepatide comparison.
Semaglutide works. It starts working within days (appetite), shows measurable results within weeks (scale), and produces transformative outcomes within months (body composition, metabolic health, cardiovascular risk). But it is not a magic injection—it is a powerful tool that works best when combined with dietary optimization, adequate protein, physical activity, and ongoing physician supervision.
If you are considering semaglutide, the most important step is a thorough medical evaluation to confirm you are a good candidate and to establish a personalized dosing and monitoring plan.
This article is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult with a licensed physician before starting any medication.
No credit card required. Live MD consult included.